Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirarubicin + ifosfamide
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**pirarubicin + ifosfamide** is a combination chemotherapy regimen primarily used in the treatment of soft tissue sarcoma. Pirarubicin is an anthracycline antibiotic similar to doxorubicin, acting mainly by intercalating into DNA and inhibiting topoisomerase II, resulting in DNA damage and apoptosis in rapidly dividing cells. Ifosfamide is an alkylating agent that causes cross-linking of DNA strands, disrupting DNA replication and cell division. This combination has been studied alongside other agents (notably etoposide) as an alternative to doxorubicin-based therapies, showing comparable response rates but with significant hematological toxicities such as leukopenia, anemia, and thrombocytopenia. The main route of administration is intravenous infusion[1][2].
- Other names
- pirarubicin + ifosfamide
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on pirarubicin + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirarubicin + ifosfamide.